Evidence map›Paper›PMID 29930023›Full record

ArticleCirculation2018

Association of Blood Pressure Measurements With Peripheral Artery Disease Events.

Nathan K Itoga, Daniel S Tawfik, Charles K Lee, Satoshi Maruyama, Nicholas J Leeper, Tara I Chang

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Circulation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00000542. Cited by 42 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 4 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000542 phase3completed

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Ran1993Registered outcomes0Posted comparisons0ConditionsCardiovascular Diseases, Coronary Disease, Diabetes Mellitus, Heart DiseasesArmsamlodipine, chlorthalidone, diet, fat-restricted, doxazosin, Inhibitors, ACE
Open the trial in the graph
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 4 syntheses or guidelines pooled it, 109 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Blood Pressure and Risk of Clinical Events in Peripheral Artery Disease.medRxiv : the preprint server for health sciences · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Nathan K ItogaDivision of Vascular Surgery, Department of Surgery (N.K.I., C.K.L., N.J.L.), Stanford University School of Medicine, CA.
Daniel S TawfikDepartment of Health Research and Policy (D.S.T., S.M.), Stanford University School of Medicine, CA.
Charles K LeeDivision of Vascular Surgery, Department of Surgery (N.K.I., C.K.L., N.J.L.), Stanford University School of Medicine, CA.
Satoshi MaruyamaDepartment of Health Research and Policy (D.S.T., S.M.), Stanford University School of Medicine, CA.
Nicholas J LeeperDivision of Vascular Surgery, Department of Surgery (N.K.I., C.K.L., N.J.L.), Stanford University School of Medicine, CA.
Tara I ChangDivision of Nephrology, Department of Medicine (T.I.C.), Stanford University School of Medicine, CA.
Stanford University · USNorwegian Womens Public Health Association · NO

Funding

T32 Training Program in Mechanisms and Innovation in Vascular DiseaseT32HL098049 · NHLBI · STANFORD UNIVERSITY · PI Nicholas James Leeper, Philip S Tsao · 2010 to 2026
$6.3M
TRAINING PROGRAM IN ACADEMIC NEPHROLOGYT32DK007357 · NIDDK · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW · 1986 to 2022
$4.8M
Mentoring Patient-Oriented Clinical Investigators in NephrologyK24DK085446 · NIDDK · STANFORD UNIVERSITY · PI CHERTOW, GLENN MATTHEW · 2010 to 2022
$1.4M
Spectrum Stanford Center for Clinical and Translational Research and EducationTL1TR001084 · NCATS · STANFORD UNIVERSITY · PI CULLEN, MARK RICHARD, GREENBERG, HARRY BERNARD · 2013 to 2017
$1.1M
Towards optimizing care for cardiovascular disease in chronic kidney diseaseK23DK095914 · NIDDK · STANFORD UNIVERSITY · PI CHANG, TARA I-HSIN · 2013 to 2017
$908k
Peripheral Arterial Disease in Older Patients with Chronic Kidney DiseaseR03DK113341 · NIDDK · STANFORD UNIVERSITY · PI CHANG, TARA I-HSIN · 2018 to 2019
$157k
NCATS NIH HHS TL1 TR001084NHLBI NIH HHS T32 HL098049NIDDK NIH HHS K23 DK095914NIDDK NIH HHS K24 DK085446NIDDK NIH HHS R03 DK113341NIDDK NIH HHS T32 DK007357
6 · The paper itself

Abstract

backgroundCurrent guidelines recommend treating hypertension in patients with peripheral artery disease (PAD) to reduce the risk of cardiac events and stroke, but the effect of reducing blood pressure on lower extremity PAD events is largely unknown. We investigated the association of blood pressure with lower extremity PAD events using data from the ALLHAT trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

methodsALLHAT investigated the effect of different antihypertensive medication classes (chlorthalidone, amlodipine, lisinopril, or doxazosin) on cardiovascular events. With the use of these data, the primary outcome in our analysis was time to first lower extremity PAD event, defined as PAD-related hospitalization, procedures, medical treatment, or PAD-related death. Given the availability of longitudinal standardized blood pressure measurements, we analyzed systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure as time-varying categorical variables (reference categories 120-129 mm Hg for SBP, 70-79 mm Hg for DBP, and 45-54 mm Hg for pulse pressure) in separate models. We used extended Cox regression with death as a competing risk to calculate the association of each blood pressure component with PAD events, and report the results as subdistribution hazard ratios and 95% CIs.

resultsThe present analysis included 33 357 patients with an average age of 67.4 years, 53.1% men, 59.7% white race, and 36.2% with diabetes mellitus. The median baseline blood pressure was 146/84 mm Hg. Participants were followed for a median of 4.3 (interquartile range, 3.6-5.3) years, during which time 1489 (4.5%) had a lower extremity PAD event, and 4148 (12.4%) died. In models adjusted for demographic and clinical characteristics, SBP <120 mm Hg was associated with a 26% (CI, 5%-52%; P=0.015) higher hazard and SBP≥160 mm Hg was associated with a 21% (CI, 0%-48%; P=0.050) higher hazard for a PAD event, in comparison with SBP 120 to 129 mm Hg. In contrast, lower, but not higher, DBP was associated with a higher hazard of PAD events: for DBP <60 mm Hg (hazard ratio, 1.72; CI, 1.38-2.16). Pulse pressure had a U-shaped association with PAD events.

conclusionsIn this reanalysis of data from ALLHAT, we found a higher rate of lower extremity PAD events with higher and lower SBP and pulse pressure and with lower DBP. Given the recent revised blood pressure guidelines advocating lower SBP targets for overall cardiovascular risk reduction, further refinement of optimal blood pressure targets specific to PAD is needed. CLINICAL

trial registrationURL: https://www.clinicaltrials.gov . Unique identifier: NCT00000542.

Indexed as

AgedAntihypertensive AgentsBlood PressureBlood Pressure DeterminationFemaleHumansHypertensionLower ExtremityMaleMiddle AgedMulticenter Studies as TopicPeripheral Arterial DiseaseRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsTime FactorsAntihypertensive Agentsblood pressurehypertensionhypotensionperipheral arterial diseasestandards

Identifiers

PMID29930023
PMCPMC6202170
OpenAlexW2809529950

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.